STEM CELL THERAPEUTIC

MEDIPOST Completes Phase 1 and 2 Clinical Trials with its Lung Disease Treatment Drug ‘PNEUMOSTEM’ in US

MEDIPOST Obtains Patent in US for its Arthritis Treatment Technique

MEDIPOST Obtains Patent in US for its Alzheimer’s Disease Treatment Drug

MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease

MEDIPOST Obtains Patent in China for its Alzheimer’s Disease Treatment Substance

MEDIPOST Obtains Patent in Canada for its ‘PNEUMOSTEM’ Used to Treat Lung Diseases

MEDIPOST Obtains Stem Cell Therapy Patent in Japan for Treating Alzheimer’s Disease

Singapore/Taiwan consecutively invited MEDIPOST to its stem cell forums

What is “CARTISTEM” used for treatment of Hiddink?

‘PNEUMOSTEM’ selected as the ‘Newly developed and promising medical technology’ by National evidence based healthcare collaborating agency

Selected as a conducting company of ‘global high-tech biomedicine industry’

MEDIPOST announced extension plans in US ’2015 Stem Cell Meeting on the Mesa’